# Reckitt Benckiser Q4 LFL net revenue growth of 6.2%

- Link: https://www.directorstalkinterviews.com/reckitt-benckiser-q4-lfl-net-revenue-growth-of-6.2/4121108250
- Published: 2023-03-01T07:46:25+00:00
- Author: Amilia Stone

**Reckitt Benckiser Group PLC **([LON:RKT](https://www.directorstalkinterviews.com/ftse-company/reckitt-benckiser-group/rkt.l))
has announced its final results.

| ** ** | **Q4 2022**
**£m** | **Q4 2022****Actual** | **Q4 2022****Change**^(3)**Constant** | **FY 2022****£m** | **FY 2022****Actual** | **FY 2022****Change^(3)****Constant** | 
| Net Revenue^(1) | 3,830 | +14.0% | +5.6% | **14,453** | **+9.2%** | **+3.9%** | 
| _Like-for-Like (LFL)__^(2)_ |  |  | _+6.2%_ | ** ** | **_ _** | **_+7.6%_** | 
| _ _ |  |  | _ _ | **_ _** | **_ _** | **_ _** | 
| **Adjusted^(2) ex IFCN China** | **_ _** | _ _ | **_ _** | **_ _** | **_ _** | **_ _** | 
| Operating Profit | ** ** | ** ** | ** ** | **3,439** | **+16.8%** | **+9.2%** | 
| Operating Profit Margin | ** ** | ** ** | ** ** | **23.8%** | **+90bps** | ** ** | 
| _ _ | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | 
| **Adjusted^(2) inc IFCN China** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | 
| Operating Profit | ** ** | ** ** | ** ** | **3,439** | **+19.5%** | **+11.7%** | 
| Total EPS (diluted) | ** ** | ** ** | ** ** | **341.7p** | **+18.4%** | ** ** | 
|  | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | 
| **IFRS** | ** ** | ** ** | ** ** | ** ** | ** ** | ** ** | 
| Operating Profit | ** ** | ** ** | ** ** | **3,249** | **_Nm_** | ** ** | 
| Operating Profit Margin | ** ** | ** ** | ** ** | **22.5%** | **_Nm_** | ** ** | 
| Total EPS (diluted) | ** ** | ** ** | ** ** | **324.7****p** | **_Nm_** | ** ** |

1.     Group excluding IFCN China net revenue growth on an IFRS basis of +14.4% 
in Q4 and +12.5% for the full year.

2.     Adjusted measures are defined on page 28

3.     Change vs prior year presented.  Constant measured on a constant exchange
rate basis (see page 28)

**Q4 Highlights**

·      **Q4 like-for-like (LFL) net revenue growth of +6.2**.  Our Hygiene GBU returned
to growth in the quarter (+1.3%) due to further improved trends in Lysol, and mid-
single digit growth in the rest of the portfolio.  Health (+6.7%) saw strong growth
in OTC brands, offset by weaker demand in China Intimate Wellness. Nutrition delivered
another strong quarter (+19.4%) with strong demand in the US and the continued turn
around in developing markets. On an IFRS basis net revenue grew by +14.0%.

**FY Highlights:**

·      **Group LFL net revenue growth of +7.6%. ** Growth was broad-based and led
by our market-leading brands across the Auto Dishwash, Fabric Additives, OTC, Intimate
Wellness, VMS and Nutrition categories.  The positive impact on net revenue from
the US Nutrition competitor supply issue is approximately +2.5%.  On an IFRS basis
net revenue grew by +9.2%.    

·      **The Group delivered a three-year CAGR of +8.2% on a LFL net revenue basis.**
This includes two consecutive years of mid-single digit growth from 70% of the portfolio
less sensitive to Covid dynamics. ** **During the year, these brands grew high-single
digits**. ** Excluding the positive impact from US IFCN, growth was mid-single digits.

·      **Hygiene LFL net revenue decline of -3.1%,** mostly due to tough comparatives
in Lysol.  Excluding Lysol, the business delivered mid-single digit growth. Lysol
saw improving trends throughout the year, and delivered net revenue growth of around
+45% above pre-pandemic levels.  On an IFRS basis net revenue grew by +0.8%.   

·      **Health LFL net revenue growth of +14.7%**, driven by a combination of strong
demand and share gains in our OTC portfolio, and continued momentum in our Intimate
Wellness and VMS brands with a stable performance in Germ Protection, which remains
around +40% ahead of pre-pandemic levels. On an IFRS basis net revenue grew by +
18.6%.

·      **Nutrition LFL net revenue growth of +22.9%**, driven by mid-single digit
growth in our Developing Markets business and around +40% growth in the US with 
strong execution amidst temporary competitor supply issues.  On an IFRS basis net
revenue grew by +10.2%.

·      **Double-digit adjusted operating profit (excluding IFCN China) growth of
+16.8%** (+9.2% on a constant FX basis) driven by strong top line growth, productivity
and positive product mix.** ** Adjusted operating margin (excluding IFCN China) 
grew by +90bps to 23.8%.  The benefit on adjusted operating profit in 2022 from 
the US Nutrition competitor supply issue is approximately +80bps.  2022 IFRS operating
margin was 22.5%.  

·      **Double-digit adjusted EPS (diluted) growth +18.4% to 341.7p,** driven by
net revenue growth, operating margin expansion, and foreign exchange tailwinds. 
On an IFRS basis total diluted EPS was 324.7p.

·      **Strong balance sheet with net debt reduced to 2.1x adjusted EBITDA. ** 
Free cash flow generation of £2.0bn (2021: £1.3bn) and cash conversion of 83% (2021:
61%).

·      **Full year dividend increased by 5% to 183.3p** (2021: 174.6p), with the
aim to deliver sustainable dividend growth in future years.

**2023 Outlook**

·      We target LFL net revenue growth of mid-single digits for the Group, excluding
the lapping of a circa 2.5% impact of the competitor supply disruption in our US
Nutrition business in 2022 (“US Nutrition impact”).

·      We expect adjusted operating margins to be in line with or slightly above
2022 levels when excluding the one-off benefit of circa 80bps in 2022 related to
US Nutrition. Within our guidance we expect to significantly increase BEI to support
an exciting innovation programme in 2023. 

> _**Commenting on the results, Nicandro Durante, Chief Executive Officer, said:**_
> “Reckitt Benckiser delivered a year of strong growth in net revenue, earnings,
> and free cash flow conversion amidst a continued challenging environment. We are
> now 28% larger than we were in 2019. Our healthy balance sheet underpins our financial
> strength, and we are delighted to grow the dividend in 2022 with the aim to deliver
> sustainable dividend growth in future years.
> We enter 2023 as a strengthened business with enhanced financial, operational 
> and brand resilience, and continued growth momentum. The benefits of our reinvigorated
> innovation pipeline and operational improvements are coming through – including
> a more agile supply chain and improved customer relationships.
> We have more to achieve, and will continue to see macroeconomic and consumer pressures
> in the year ahead.  However, our financial, operational and brand strength position
> us well for the future. We have a strong innovation pipeline in 2023 which will
> be supported by increased brand equity investment.  We remain fully focused on
> the delivery of our strategy, to protect, heal and nurture in the relentless pursuit
> of a cleaner, healthier world.”

**FY 2022 RESULTS PRESENTATION TODAY**

There will be a results presentation for analysts and investors at 08:30 GMT which
will be held at The Auditorium, Bank of America, 2 King Edward Street, London, EC1A
1HQ.

To attend in person, please email your details to ir@reckitt.com to register.

For those wishing to follow the webcast please click on the link below:

https://www.reckitt.com/investors/results-and-presentations/

Alternatively, dial in details are as follows:

United Kingdom:                       0800 640 6441

All other locations:                    +44 20 3936 2999

Participant access code                        910902

Share on:
